HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Farese, A. M. Articles by MacVittie, T. J. Search for Related Content PubMed PubMed Citation Articles by Farese, A. M. Articles by MacVittie, T. J.

A Single Dose of Pegylated Leridistim Significantly Improves Neutrophil Recovery in Sublethally Irradiated Rhesus Macaques

^a University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, USA;
^b Pharmacia Corp., St. Louis, Missouri, USA

Key Words. Leridistim • Myelopoietin • Myelosuppression • Rhesus • Neutrophil

Correspondence: Ann M. Farese, M.S., University of Maryland, Greenebaum Cancer Center, 655 West Baltimore Street, BRB 7-049, Baltimore, Maryland USA, 21201; Telephone: 410-328-5347; Fax: 410-328-5488; e-mail: afarese{at}umaryland.edu

Leridistim, a member of the myelopoietin family of dual receptor agonists that binds interleukin-3 and G-CSF receptors, has been shown to enhance hematopoietic activity in rhesus monkeys above that observed with either cytokine alone or in combination. This study demonstrated the ability of a pegylated form of leridistim (peg-leridistim), administered s.c., as a single- or two-dose regimen separated by 4 or 7 days, to significantly improve neutrophil recovery following radiation-induced myelosuppression. Rhesus macaques were total body x-irradiated (250 kVp, TBI) to 600 cGy. Following TBI, two groups received peg-leridistim (n = 5) or leridistim (n = 4) at a dose of 600 µg/kg on day 1, while two other groups (both n = 4) received peg-leridistim at 200 µg/kg on day 1 and day 4, or day 1 and day 7. The irradiation controls (n = 7) received 0.1% autologous serum for 18 days. All peg-leridistim treatment schedules significantly improved all neutrophil-related parameters following TBI as compared with nontreated controls and were equivalent in effect when compared among themselves. Administration of a single high dose or two separate lower doses of peg-leridistim significantly improved neutrophil regeneration, in a manner equal to that of conventional daily or abbreviated every-other-day administration of leridistim in this nonhuman primate model of severe myelosuppression.

This article has been cited by other articles:

				T. J. Smith, J. Khatcheressian, G. H. Lyman, H. Ozer, J. O. Armitage, L. Balducci, C. L. Bennett, S. B. Cantor, J. Crawford, S. J. Cross, et al. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline J. Clin. Oncol., July 1, 2006; 24(19): 3187 - 3205. [Abstract] [Full Text] [PDF]

				J. K. Waselenko, T. J. MacVittie, W. F. Blakely, N. Pesik, A. L. Wiley, W. E. Dickerson, H. Tsu, D. L. Confer, C. N. Coleman, T. Seed, et al. Medical Management of the Acute Radiation Syndrome: Recommendations of the Strategic National Stockpile Radiation Working Group Ann Intern Med, June 15, 2004; 140(12): 1037 - 1051. [Abstract] [Full Text] [PDF]

				A. M. Farese, T. J. MacVittie, L. Roskos, and R. B. Stead Hematopoietic Recovery Following Autologous Bone Marrow Transplantation in a Nonhuman Primate: Effect of Variation in Treatment Schedule with PEG-rHuMGDF Stem Cells, January 1, 2003; 21(1): 79 - 89. [Abstract] [Full Text] [PDF]

				N. Dainiak, J. K. Waselenko, J. O. Armitage, T. J. MacVittie, and A. M. Farese The Hematologist and Radiation Casualties Hematology, January 1, 2003; 2003(1): 473 - 496. [Abstract] [Full Text] [PDF]